Shandong New Element

New Element Biopharma is a clinical-stage biopharmaceutical company focused on developing best-in-class small molecule drugs for metabolic diseases and inflammation. Headquartered in Shenzhen with a major manufacturing and industrialization base in Shandong, the company's lead program is ABP-671, a highly potent URAT1 inhibitor currently in global Phase 3 clinical trials for the treatment of chronic gout and hyperuricemia. ABP-671 is designed to provide a safer and more effective alternative to existing urate-lowering therapies, which often suffer from limited efficacy or significant safety concerns. The company's pipeline also includes candidates for other metabolic and inflammatory conditions, supported by a strong investor base including Sequoia China and Matrix Partners China. New Element Biopharma leverages its internal R&D capabilities to address large unmet medical needs in the global metabolic health market.